Refractory Tumor Clinical Trial
Official title:
Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway)
This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.
The individuals recruited in the present study are with solid tumor, mainly including two parts: first, rare tumor without standard recommended treatment such as atypical fibrous histiocytoma; second, common tumor after multiple line of therapy such as lung cancer, gastric cancer, colorectal cancer, etc. All patients have no any standard therapy based on NCCN guideline when recruiting. Next-generation sequence was used to detect druggable molecular event including gene mutation, gene fusion, amplification, etc. Then patients with molecular events were treated with corresponding targeted drug and followed-up, and not limited tumor type. PD-1/L1 inhibior plus anti-angiogenic agent was used in patients without durgguable targets. The efficacy and safety of these regimens were evaluated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05099549 -
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT06202599 -
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
|
||
| Recruiting |
NCT04900519 -
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03158324 -
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077
|
Phase 2 | |
| Active, not recruiting |
NCT04239092 -
9-ING-41 in Pediatric Patients With Refractory Malignancies.
|
Phase 1 | |
| Withdrawn |
NCT04809012 -
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06047860 -
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05767684 -
Neoantigen Derived DCs as Cancer Treatment
|
Phase 1 | |
| Completed |
NCT03415477 -
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05752552 -
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
|
Phase 1 | |
| Completed |
NCT02564198 -
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06098651 -
A Study of DCR-STAT3 in Adults With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05790447 -
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
|
Phase 2 |